RxDoctor Payments Data

Richard Garmany, MD

Cardiovascular Disease · Grand Junction, CONPI 1962446302

Payments from drug & device makers

$5,178in general payments, 2019–2025

Across 128 payments — averaging $40.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$185
  • Novartis$151
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$150
  • Impulse Dynamics (USA) Inc.$143
  • plus $415 from 12 others

What the payments were for

  • Travel & lodging$1,95038%
  • Food & beverage$3,22262%
  • Entertainment$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,178 in reported general payments places this provider in the 65th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$280,130
Medicare patients
1,300
Services billed
4,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban521$618,210
EntrestoSacubitril/Valsartan230$323,795
JardianceEmpagliflozin82$96,414
XareltoRivaroxaban65$85,030
FarxigaDapagliflozin Propanediol22$33,298
Repatha SureclickEvolocumab45$28,922
Metoprolol Succinate453$7,934
Dofetilide19$6,207
Flecainide Acetate100$3,975
Losartan Potassium332$3,267
PradaxaDabigatran Etexilate Mesylate13$2,534
Eplerenone30$2,318
Atorvastatin Calcium249$2,193
Potassium Chloride54$2,180
Spironolactone245$2,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$618,210521 claims
NovartisEntresto$151$323,795230 claims
Johnson & JohnsonXarelto$52$85,03065 claims
AstraZenecaFarxiga$16$33,29822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →